Literature DB >> 17051150

Structure of C3b in complex with CRIg gives insights into regulation of complement activation.

Christian Wiesmann1, Kenneth J Katschke, JianPing Yin, Karim Y Helmy, Micah Steffek, Wayne J Fairbrother, Scott A McCallum, Lizette Embuscado, Laura DeForge, Philip E Hass, Menno van Lookeren Campagne.   

Abstract

The complement system is a key part of the innate immune system, and is required for clearance of pathogens from the bloodstream. After exposure to pathogens, the third component of the complement system, C3, is cleaved to C3b which, after recruitment of factor B, initiates formation of the alternative pathway convertases. CRIg, a complement receptor expressed on macrophages, binds to C3b and iC3b mediating phagocytosis of the particles, but it is unknown how CRIg selectively recognizes proteolytic C3-fragments and whether binding of CRIg to C3b inhibits convertase activation. Here we present the crystal structure of C3b in complex with CRIg and, using CRIg mutants, provide evidence that CRIg acts as an inhibitor of the alternative pathway of complement. The structure shows that activation of C3 induces major structural rearrangements, including a dramatic movement (>80 A) of the thioester-bond-containing domain through which C3b attaches to pathogen surfaces. We show that CRIg is not only a phagocytic receptor, but also a potent inhibitor of the alternative pathway convertases. The structure provides insights into the complex macromolecular structural rearrangements that occur during complement activation and inhibition. Moreover, our structure-function studies relating the structural basis of complement activation and the means by which CRIg inhibits the convertases provide important clues to the development of therapeutics that target complement.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17051150     DOI: 10.1038/nature05263

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  98 in total

1.  The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.

Authors:  Masha Fridkis-Hareli; Michael Storek; Eran Or; Richard Altman; Suresh Katti; Fang Sun; Tao Peng; Jeff Hunter; Krista Johnson; Yi Wang; Ante S Lundberg; Gaurav Mehta; Nirmal K Banda; V Michael Holers
Journal:  Mol Immunol       Date:  2018-12-01       Impact factor: 4.407

2.  Crystal structure of C5b-6 suggests structural basis for priming assembly of the membrane attack complex.

Authors:  Alexander E Aleshin; Richard G DiScipio; Boguslaw Stec; Robert C Liddington
Journal:  J Biol Chem       Date:  2012-04-12       Impact factor: 5.157

3.  Inhibiting alternative pathway complement activation by targeting the factor D exosite.

Authors:  Kenneth J Katschke; Ping Wu; Rajkumar Ganesan; Robert F Kelley; Mary A Mathieu; Philip E Hass; Jeremy Murray; Daniel Kirchhofer; Christian Wiesmann; Menno van Lookeren Campagne
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

4.  Molecular mechanisms of complement evasion: learning from staphylococci and meningococci.

Authors:  Davide Serruto; Rino Rappuoli; Maria Scarselli; Piet Gros; Jos A G van Strijp
Journal:  Nat Rev Microbiol       Date:  2010-06       Impact factor: 60.633

5.  Convertase inhibitory properties of Staphylococcal extracellular complement-binding protein.

Authors:  Ilse Jongerius; Brandon L Garcia; Brian V Geisbrecht; Jos A G van Strijp; Suzan H M Rooijakkers
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

Review 6.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

7.  Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex.

Authors:  Nick S Laursen; Kasper R Andersen; Ingke Braren; Edzard Spillner; Lars Sottrup-Jensen; Gregers R Andersen
Journal:  EMBO J       Date:  2011-01-07       Impact factor: 11.598

Review 8.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

9.  Development of Sjogren's syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6.NOD-Aec1Aec2 mice is dependent on complement component-3.

Authors:  Cuong Q Nguyen; Hyuna Kim; Janet G Cornelius; Ammon B Peck
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

10.  Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry.

Authors:  Michael C Schuster; Daniel Ricklin; Krisztián Papp; Kathleen S Molnar; Stephen J Coales; Yoshitomo Hamuro; Georgia Sfyroera; Hui Chen; Michael S Winters; John D Lambris
Journal:  Mol Immunol       Date:  2008-05-05       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.